Correlation between percutaneous biopsy and final histopathology for retroperitoneal sarcoma: a single-centre study.
percutaneous biopsy
retroperitoneal
sarcoma
surgical oncology
Journal
ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
30
10
2019
revised:
07
01
2020
accepted:
14
01
2020
pubmed:
18
2
2020
medline:
15
5
2021
entrez:
18
2
2020
Statut:
ppublish
Résumé
Retroperitoneal sarcomas are rare soft tissue tumours accounting for 10-15% of soft tissue sarcomas. Patient prognosis and treatment recommendations (including extent of surgery and neoadjuvant strategies) are determined by the pre-operative histopathological subtype and grade obtained from biopsy and thus it is important to understand the accuracy of biopsy in retroperitoneal masses. This study presents a case series of primary retroperitoneal sarcomas managed at Peter MacCallum Cancer Centre (PMCC) between 2008 and 2019. Statistical analyses were performed to determine correlation between histopathology from percutaneous biopsy and surgical excision. A total of 117 patients who underwent percutaneous core biopsy and surgical excision of retroperitoneal sarcoma were included. Diagnostic accuracy varied with histopathological diagnosis, but overall precise concordance between biopsy and final histopathology was seen in 61% (κ = 0.57). Biopsy was most sensitive for identifying well-differentiated liposarcoma (WDLPS) (sensitivity 85%, 95% CI 0.06-0.96) and leiomyosarcoma (sensitivity 81%, 95% CI 0.54-0.96) and was least sensitive for identifying de-differentiated liposarcoma (DDLPS) (sensitivity 40%, 95% CI 0.25-0.56). Overall agreement between biopsy and final histopathology increased with use of PET/CT scan pre-biopsy and with use of fluorescence in situ hybridisation testing on biopsy, however, neither test improved recognition of de-differentiated components within WD/DDLPS on core biopsy. Pre-operative biopsy is important for clinical decision making in the treatment of retroperitoneal sarcoma. A significant portion of patients with a WDLPS will have a de-differentiated component identified at the time of resection that was not identified on initial biopsy.
Sections du résumé
BACKGROUND
Retroperitoneal sarcomas are rare soft tissue tumours accounting for 10-15% of soft tissue sarcomas. Patient prognosis and treatment recommendations (including extent of surgery and neoadjuvant strategies) are determined by the pre-operative histopathological subtype and grade obtained from biopsy and thus it is important to understand the accuracy of biopsy in retroperitoneal masses.
METHODS
This study presents a case series of primary retroperitoneal sarcomas managed at Peter MacCallum Cancer Centre (PMCC) between 2008 and 2019. Statistical analyses were performed to determine correlation between histopathology from percutaneous biopsy and surgical excision.
RESULTS
A total of 117 patients who underwent percutaneous core biopsy and surgical excision of retroperitoneal sarcoma were included. Diagnostic accuracy varied with histopathological diagnosis, but overall precise concordance between biopsy and final histopathology was seen in 61% (κ = 0.57). Biopsy was most sensitive for identifying well-differentiated liposarcoma (WDLPS) (sensitivity 85%, 95% CI 0.06-0.96) and leiomyosarcoma (sensitivity 81%, 95% CI 0.54-0.96) and was least sensitive for identifying de-differentiated liposarcoma (DDLPS) (sensitivity 40%, 95% CI 0.25-0.56). Overall agreement between biopsy and final histopathology increased with use of PET/CT scan pre-biopsy and with use of fluorescence in situ hybridisation testing on biopsy, however, neither test improved recognition of de-differentiated components within WD/DDLPS on core biopsy.
CONCLUSIONS
Pre-operative biopsy is important for clinical decision making in the treatment of retroperitoneal sarcoma. A significant portion of patients with a WDLPS will have a de-differentiated component identified at the time of resection that was not identified on initial biopsy.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
497-502Informations de copyright
© 2020 Royal Australasian College of Surgeons.
Références
Dumitra S, Gronchi A. The diagnosis and management of retroperitoneal sarcoma. Oncology 2018; 32: 464-9.
Trans-Atlantic RPS Working Group. Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the trans-Atlantic RPS working group. Ann. Surg. Oncol. 2015; 22: 256-63.
Mota M, Bezerra R, Garcia M. Practical approach to primary retroperitoneal masses in adults. Radiol. Bras. 2018; 51: 391-400.
Cohen J. Weighted kappa: nominal scale agreement provision for scaled disagreement or partial credit. Psychol. Bull. 1968; 70: 213-20.
Fletcher C, Bridge J, Hogendoorn P, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone, Fourth edn. Lyon: IARC Press, 2013.
Snow H, Hitchen T, Head J et al. Treatment of patients with primary retroperitoneal sarcoma: predictors of outcome from an Australian specialist sarcoma centre. ANZ J. Surg. 2018; 88: 1151-7.
Almond L, Tirotta F, Tattersall H et al. Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma. Br. J. Surg. 2019; 106: 395-403.
Ikoma N, Torres K, Somaiah N et al. Accuracy of preoperative percutaneous biopsy for the diagnosis of retroperitoneal Liposarcoma subtypes. Ann. Surg. Oncol. 2015; 22: 1068.
Alford S, Choong P, Chander S et al. Value of PET scan in patients with retroperitoneal sarcoma treated with preoperative radiotherapy. Eur. J. Surg. Oncol. 2012; 38: 176-80.
Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur. J. Nucl. Med. Mol. Imaging 2006; 33: 1290-5.
Nieweg O, van Ginkel R, Hoekstra H, Paans A, Molenaar W et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J. Nucl. Med. 1996; 37: 257-61.
Schwarzbach M, Dimitrakopoulou-Strauss A, Willeke F et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann. Surg. 2000; 231: 380-6.
Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F] fluorodeoxyglucose positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 2006; 33: 683-91.
Ioannidis J, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J. Nuclear Med. 2003; 44: 717-24.
Eary J, Conrad E. PET imaging: update on sarcomas. Oncology 2007; 21: 249-52.
Asif A, Mushtaq S, Hassan U et al. Fluorescence in situ hybridization (FISH) for differential diagnosis of soft tissue sarcomas. Asian Pac. J. Cancer Prev. 2018; 19: 655-60.
Clay MR, Martinez AP, Weiss SW, Edgar MA. MDM2 amplification in problematic Lipomatous tumors: analysis of FISH testing criteria. Am. J. Surg. Pathol. 2015; 39: 1433-9.
Kimura H, Yamamoto N, Shirai T et al. Detection of MDM2 gene amplification in soft tissue sarcoma by FISH. J. Clin. Oncol. 2014; 32: 10562.
Thway K, Wang J, Swansbury J, Min T, Fisher C. Fluorescence in situ hybridization for MDM2 amplification as a routine ancillary diagnostic tool for suspected well-differentiated and dedifferentiated liposarcomas: experience at a tertiary center. Sarcoma 2015; 2015: 1-10.
Weaver J, Downs-Kelly E, Goldblum J et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod. Pathol. 2008; 21: 943-9.
Yu J, Colborne S, Hughes C, Morin G, Nielsen T. The FUS-DDIT3 interactome in myxoid liposarcoma. Neoplasia 2019; 21: 740-51.
National Institute for Health and Clinical Excellence (NICE). Improving outcomes for people with sarcoma. The manual. NICE, 2006.
Cancer Council Australia Sarcoma Guidelines Working Party. Clinical Practice Guidelines for the Management of Adult Onset Sarcoma. Sydney: Cancer Council Australia. 2013.